Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

OncoProTools

Financiado

Cerrado

Protease‐guided tumor targeting tools to revolutionize cancer diagnosis and trea...

Protease‐guided tumor targeting tools to revolutionize cancer diagnosis and treatment. Europe has a high cancer burden: in 2020, 2.7 million EU citizens were diagnosed with the disease and 1.3 million lost their lives to it. This toll is expected to increase further, mainly because Europe's population is ageing: by... ver más

31/08/2026

UANTWERPEN

Presupuesto desconocido

Líder del proyecto

UNIVERSITEIT ANTWERPEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-09-01

HORIZON-MSCA-2021-DN-01-01: MSCA Doctoral Networks 2021 ExpectedOutcome:

I+D

Cerrada hace 3 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

UANTWERPEN

Lider

Proyectos interesantes

CANCER-ID

Medical Technol...

Data Science

21M€ Cerrado

FG_WIT

Medical Technol...

Data Science

75K€ Cerrado

CANCER-ID

Medical Technol...

Data Science

21M€ Cerrado

IMPED

Medical Technol...

Data Science

225K€ Cerrado

Oncosmart

Medical Technol...

Data Science

71K€ Cerrado

CAPER/BREAST CANCE

Medical Technol...

Data Science

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 47 meses Fecha Inicio: 2022-09-01
Fecha Fin: 2026-08-31

Líder del proyecto

UNIVERSITEIT ANTWERPEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Europe has a high cancer burden: in 2020, 2.7 million EU citizens were diagnosed with the disease and 1.3 million lost their lives to it. This toll is expected to increase further, mainly because Europe's population is ageing: by 2035, cancer will be the leading cause of death in the EU. In 2021, the EC published its ‘Europe's Beating Cancer Plan’ (EBCP), calling for a big push in cancer research. Cancer diagnostics and therapeutics should rapidly become more effective and selective, patient-friendly and personalized.All these goals are directly addressed by developing better tumor targeting strategies. Typically, they consist of equipping diagnostics and therapeutics with a vector unit. The vector unit binds to a protein that is overexpressed on cancer cells or in the Tumor Micro-Environment (TME), causing the diagnostic or therapeutic payload to accumulate in the tumor. Over the last decades, huge effort has gone in approaches that use antibodies as vectors, but return-on-investment has overall been rather poor. Exciting, recent innovations rely on small molecule vectors that target TME proteases. Proteases are ideal candidates for tumor targeting: they are often strongly overexpressed in the TME and possess an active site that allows high-affinity anchoring of vectors. Members of this consortium have played a leading role in these developments.OncoProTools wants to force breakthroughs in cancer diagnosis and therapy by:1) Exploring innovative venues for protease targeting in CAR T cell therapy. 2) Discovering novel vectors that bind to other TME proteases: cathepsins S, B, L and granzyme B3) Personalize applications of protease targeting: deliver innovative diagnostics through deeper understanding of TME biology.At the same time, OncoProTools will deliver a training program that truly captures the MSCA values, to 10 Doctoral Candidates. They will be provided with all capabilities to become leaders of tomorrow's R&I in Europe.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores